Abstract:The Kirsten rat sarcoma viral (KRAS) oncogene is the most frequently mutated isoform of RAS, associated with 85 % of RAS-driven cancers. KRAS functions as a signaling hub, participating in various cellular signaling pathways and regulating a wide range of important activities, including cell proliferation, differentiation, growth, metabolism, and migration. Despite being the most frequently altered oncogenic protein in solid tumors, over the past four decades, KRAS has historically been considered "undruggable" owing to a lack of pharmacologically targetable pockets within the mutant isoforms. However, improvements in drug design and development have culminated in the development of selective inhibitors for KRAS mutants. Recent developments have led to the successful targeting of the KRASG12C mutant through covalent inhibitors that exploit the unique cysteine residue introduced by the mutation at 12th position. These inhibitors bind covalently to C12, locking KRAS in its inactive GDP-bound state and preventing downstream signaling. Some of these inhibitors have shown encouraging results in KRASG12C mutant cancer patients but suffer from drug resistance, toxicity, and low therapeutic efficacy. Recently, there have been great advancements in the discovery of drugs that directly target the switch I (S-I), switch-II (S-II) and S-I/II interface sites of KRAS mutant proteins. These include KRASG12C inhibitors like AMG510 (Sotorasib) and MRTX849 (Adagrasib), which have got FDA approval for non-small cell lung cancer harboring the KRASG12C mutation. There is no approved drug for cancers harboring other KRAS mutations, although efforts have expanded to target other KRAS mutations and the Switch I/II interface, aiming to disrupt KRAS-driven oncogenic signaling. Structure-activity relationship (SAR) studies have been instrumental in optimizing the binding affinity, selectivity, and pharmacokinetic properties of these inhibitors, leading to the development of promising therapeutic agents like Sotorasib and Adagrasib. This review provides an overview of the KRAS pathway, KRAS binding sites, strategies for direct and indirect inhibition using small molecules, and SAR based on the co-crystal structures of inhibitors with KRAS mutants which is expected to offer new hope for patients with KRAS-driven cancers through the development of new KRAS-targeted drugs.

Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges

Targeting KRAS in cancer

From bench to bedside: current development and emerging trend of KRAS-targeted therapy

Structural perspectives on recent breakthrough efforts toward direct drugging of RAS and acquired resistance

KRAS mutation: from undruggable to druggable in cancer

Targeting RAS mutants in malignancies: successes, failures, and reasons for hope

Drugging KRAS: current perspectives and state-of-art review

Eliminating oncogenic RAS: back to the future at the drawing board

Recent advances in the development of inhibitors targeting KRAS-G12C and its related pathways

More to the RAS Story: KRASG12C Inhibition, Resistance Mechanisms, and Moving Beyond KRASG12C

Targeting KRAS in Colorectal Cancer

Multiple medicinal chemistry strategies of targeting KRAS: State-of-the art and future directions

The path to the clinic: a comprehensive review on direct KRASG12C inhibitors

Targeting Mutant Kirsten Rat Sarcoma Viral Oncogene Homolog in Non-Small Cell Lung Cancer: Current Difficulties, Integrative Treatments and Future Perspectives

Targeting KRAS: Crossroads of Signaling and Immune Inhibition

The next-generation KRAS inhibitors…What comes after sotorasib and adagrasib?

Inhibitors of the GTPase KRASG12C in Cancer: a Patent Review (2019-2021).

Targeting KRAS Mutant Cancers: from Druggable Therapy to Drug Resistance

Insights into Direct KRAS Inhibition Strategies for Cancer Treatment

Covalent inhibitor targets KRasG12C: A new paradigm for drugging the undruggable and challenges ahead

Structural insights into small-molecule KRAS inhibitors for targeting KRAS mutant cancers